Federico Innocenti

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. ncbi Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer
    Wei Peng Yong
    Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 60:811-9. 2007
  2. pmc Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients
    Romano Danesi
    Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Via Roma 55, Italy
    Br J Clin Pharmacol 53:508-18. 2002
  3. ncbi UGT1A1 genotyping in patients undergoing treatment with irinotecan
    Federico Innocenti
    University of Chicago, USA
    Clin Adv Hematol Oncol 3:843-4. 2005
  4. ncbi Effects of green tea compounds on irinotecan metabolism
    Snezana Mirkov
    Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Drug Metab Dispos 35:228-33. 2007
  5. ncbi Irinotecan treatment in cancer patients with UGT1A1 polymorphisms
    Federico Innocenti
    Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, Cancer Research Center, University of Chicago, Chicago, Illinois, USA
    Oncology (Williston Park) 17:52-5. 2003
  6. ncbi Challenges in the development and use of pharmacogenomic markers in oncology
    Federico Innocenti
    Section of Hematology Oncology, Department of Medicine, Cancer Research Center, University of Chicago, Illinois 60637, USA
    J Support Oncol 5:15-6. 2007
  7. pmc Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics
    Federico Innocenti
    The University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 27:2604-14. 2009
  8. ncbi Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping
    Federico Innocenti
    The University of Chicago, Committee on Clinical Pharmacology and Pharmacogenomics, Chicago, IL, USA
    Pharmacogenomics 7:1211-21. 2006
  9. pmc The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds
    Federico Innocenti
    Department of Medicine, The University of Chicago, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 63:881-7. 2009
  10. pmc Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene
    Federico Innocenti
    Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
    Pharmacogenet Genomics 18:683-97. 2008

Collaborators

Detail Information

Publications54

  1. ncbi Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer
    Wei Peng Yong
    Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 60:811-9. 2007
    ..Hence, this study was designed to evaluate if pharmacokinetic modulation of oral etoposide with ketoconazole could lead to a favorable alteration of etoposide pharmacokinetics, and to assess the feasibility and safety of this approach...
  2. pmc Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients
    Romano Danesi
    Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Via Roma 55, Italy
    Br J Clin Pharmacol 53:508-18. 2002
    ..To investigate the pharmacokinetics and pharmacodynamics of epirubicin and paclitaxel in combination, as well as the effects of paclitaxel and its vehicle Cremophor EL on epirubicin metabolism...
  3. ncbi UGT1A1 genotyping in patients undergoing treatment with irinotecan
    Federico Innocenti
    University of Chicago, USA
    Clin Adv Hematol Oncol 3:843-4. 2005
  4. ncbi Effects of green tea compounds on irinotecan metabolism
    Snezana Mirkov
    Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Drug Metab Dispos 35:228-33. 2007
    ..Catechins do not induce CYP3A4 activity. The effect of acute and prolonged use of green tea on the pharmacokinetics of irinotecan in patients remains to be evaluated...
  5. ncbi Irinotecan treatment in cancer patients with UGT1A1 polymorphisms
    Federico Innocenti
    Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, Cancer Research Center, University of Chicago, Chicago, Illinois, USA
    Oncology (Williston Park) 17:52-5. 2003
    ..The results of these association studies showed that preliminary genotyping of the (TA)n polymorphism might predict the occurrence of toxicity in genetically predisposed patients...
  6. ncbi Challenges in the development and use of pharmacogenomic markers in oncology
    Federico Innocenti
    Section of Hematology Oncology, Department of Medicine, Cancer Research Center, University of Chicago, Illinois 60637, USA
    J Support Oncol 5:15-6. 2007
  7. pmc Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics
    Federico Innocenti
    The University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 27:2604-14. 2009
    ..We aim to identify genetic variation, in addition to the UGT1A1*28 polymorphism, that can explain the variability in irinotecan (CPT-11) pharmacokinetics and neutropenia in cancer patients...
  8. ncbi Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping
    Federico Innocenti
    The University of Chicago, Committee on Clinical Pharmacology and Pharmacogenomics, Chicago, IL, USA
    Pharmacogenomics 7:1211-21. 2006
    ....
  9. pmc The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds
    Federico Innocenti
    Department of Medicine, The University of Chicago, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 63:881-7. 2009
    ..We studied whether the 4330T>C variant confers altered drug sensitivity in vitro...
  10. pmc Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene
    Federico Innocenti
    Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
    Pharmacogenet Genomics 18:683-97. 2008
    ..The genetic basis of interindividual variability in UGT2B7 function is unknown. This study aimed to discover novel gene variants of functional significance...
  11. ncbi Lack of association between common polymorphisms in UGT1A9 and gene expression and activity
    Jacqueline Ramirez
    Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Drug Metab Dispos 35:2149-53. 2007
    ..Our data demonstrate that the common I399C>T and-118T(9>10) polymorphisms do not explain interindividual variation in hepatic UGT1A9 activity and mRNA expression and are in complete LD in the donor liver samples we studied...
  12. ncbi UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers
    Andrea L Yoder Graber
    Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Pharmacogenet Genomics 17:619-27. 2007
    ..The aims of this study were to determine the T4 glucuronidation ability of all commercially available human UGTs, and investigate the relationship between genetic polymorphisms in UGT1A1 and UGT1A9 and T4 glucuronidation in human livers...
  13. ncbi Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes
    Jacqueline Ramirez
    Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Pharmacogenet Genomics 16:79-86. 2006
    ..The indel at -53 affects the basal phenotype and appears to limit the hepatocyte capability of maximal induction after phenobarbital. However, variants at -53, -3156 and -3279 are not associated with variability in UGT1A1 inducibility...
  14. ncbi Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes
    Federico Innocenti
    Department of Medicine, University of Chicago, Chicago, IL, USA
    Pharmacogenet Genomics 15:295-301. 2005
    ..SN-38, the active metabolite of the anticancer agent irinotecan, is metabolized by both UGT1A1 and UGT1A9. We aim to characterize the UGT1A9-UGT1A1 haplotypes in Asians and Caucasians and gain insights on their functional consequences...
  15. ncbi Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines
    Wanqing Liu
    Department of Medicine, The University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Clin Cancer Res 13:6788-95. 2007
    ..We aimed to determine if there are interactions between EGFR expression, mutations, polymorphisms, and gene amplification, and whether these factors are associated with variability in response to EGFR inhibitors...
  16. pmc R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9
    Wei Peng Yong
    Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, IL 60637, USA
    Eur J Cancer 45:1904-8. 2009
    ..We report eight subjects who experienced significant elevation of INR while receiving concomitant R(+)XK469 and warfarin. The aim of the study is to investigate whether R(+)XK469 interacts with S-warfarin by inhibition of CYP2C9...
  17. ncbi Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups
    Federico Innocenti
    Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, Cancer Research Center, The University of Chicago, Chicago, IL 60637, USA
    Pharmacogenetics 12:725-33. 2002
    ..This study showed that (i) common promoter variants are in linkage disequilibrium and (ii) the haplotype structure of promoter is probably different between Caucasians and African-Americans...
  18. ncbi A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine
    Michael B Sawyer
    Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL, USA
    Clin Pharmacol Ther 73:566-74. 2003
    ..045 and P =.004, respectively). Interindividual differences in morphine glucuronidation may be the result of genetic variation in UGT2B7, and further studies are indicated...
  19. ncbi Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
    Federico Innocenti
    Department of Medicine, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA
    J Clin Oncol 22:1382-8. 2004
    ..UDP-glucuronosyltransferase 1A1 (UGT1A1) catalyzes the glucuronidation of the active metabolite SN-38. This study prospectively evaluated the association between the prevalence of severe toxicity and UGT1A1 genetic variation...
  20. pmc A genome-wide integrative study of microRNAs in human liver
    Eric R Gamazon
    Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
    BMC Genomics 14:395. 2013
    ..The study of microRNAs in human liver tissue promises to clarify the therapeutic and diagnostic value of this important regulatory mechanism of gene expression...
  21. pmc A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours
    Samir D Undevia
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
    Eur J Cancer 44:1684-92. 2008
    ..Preclinical studies suggested that efficacy was independent of schedule but that toxicity was decreased by dividing the dose...
  22. pmc Ethnic differences and functional analysis of MET mutations in lung cancer
    Soundararajan Krishnaswamy
    Department of Medicine, The University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 15:5714-23. 2009
    ....
  23. pmc Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue
    Federico Innocenti
    Cancer Research Center, Committee on Clinical Pharmacology and Pharmacogenomics, Department of Medicine, The University of Chicago, Chicago, Illinois, United States of America
    PLoS Genet 7:e1002078. 2011
    ..In general, the work presented here will be valuable for future efforts to precisely identify and functionally characterize genetic contributions to a variety of complex traits...
  24. ncbi CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes
    Jacqueline Ramirez
    University of Chicago, Department of Medicine, Section of Hematology Oncology, 5841 S Maryland Avenue, MC2115, Chicago, IL 60637, USA
    Drug Metab Dispos 32:930-6. 2004
    ..We conclude that normeperidine formation in human liver microsomes is mainly catalyzed by CYP2B6 and CYP3A4, with a minor contribution from CYP2C19...
  25. pmc The role of pharmacogenetics in cancer therapeutics
    Wei Peng Yong
    University of Chicago, Committee on Clinical Pharmacology and Pharmacogenomics, Department of Medicine and Cancer Research Center, Chicago, IL 60637, USA
    Br J Clin Pharmacol 62:35-46. 2006
    ....
  26. ncbi Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes
    Wei Peng Yong
    Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, IL 60637, USA
    Clin Cancer Res 11:6699-704. 2005
    ..This study investigates whether ketoconazole contributes to the increase in SN-38 formation by inhibiting SN-38 glucuronidation...
  27. ncbi Pharmacogenomics: road to anticancer therapeutics nirvana?
    Apurva A Desai
    Department of Medicine, The University of Chicago, Chicago, IL, USA
    Oncogene 22:6621-8. 2003
    ..This review discusses the role of genetic variants of UGT1A1, TS and EGFR to exemplify the potential impact of phramacogenomics on the field of anticancer therapeutics...
  28. ncbi A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter
    Wanqing Liu
    Department of Medicine, University of Chicago, IL 60637, USA
    Cancer Res 65:46-53. 2005
    ..Our findings have implications for cancer etiology and therapy and may also be relevant to the inherited susceptibility of other common diseases...
  29. pmc Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer
    Dylan M Glubb
    Department of Medicine, University of Chicago, USA
    Clin Cancer Res 17:5257-67. 2011
    ..As angiogenesis is a host-driven process, functional heritable variation in KDR, the gene encoding VEGFR-2, may affect VEGFR-2 function and, ultimately, the extent of tumor angiogenesis...
  30. pmc The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients
    Jacqueline Ramirez
    Department of Medicine, Section of Hematology Oncology, University of Chicago, 5841 S Maryland Avenue, MC2115, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 68:1629-32. 2011
    ..Combination treatment may potentiate their antitumor effect and protect against irinotecan's intestinal toxicity. We investigated whether thalidomide can modulate the pharmacokinetics of irinotecan and metabolites...
  31. ncbi Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism
    Wanqing Liu
    Department of Medicine, The University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Clin Cancer Res 9:1009-12. 2003
    ..Therefore, the evaluation of the allelic distribution of this polymorphism in populations of various ethnic origins will be crucial to understand the interindividual variability in EGFR expression...
  32. ncbi A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital
    Federico Innocenti
    Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, IL 60637, USA
    Clin Pharmacol Ther 76:490-502. 2004
    ..Five partial responses were observed. Pharmacokinetic modulation of irinotecan with cyclosporine and phenobarbital has been demonstrated; further studies are necessary to evaluate whether this strategy improves the therapeutic index...
  33. pmc Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy
    Jacqueline Ramirez
    Department of Medicine, The University of Chicago, 5841 S Maryland Avenue, MC2115, Chicago, IL 60637, USA
    Future Oncol 6:563-85. 2010
    ....
  34. pmc Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms
    Wei Zhang
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, United States of America
    PLoS ONE 2:e396. 2007
    ....
  35. ncbi A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer
    Apurva A Desai
    Section of Hematology Oncology, Department of Medicine, University of Chicago, 5841 S Maryland Ave, MC 2115, IL 60637 1470, USA
    Cancer Chemother Pharmacol 54:377-84. 2004
    ..We performed this phase I trial to determine if ketoconazole-mediated CYP3A4 inhibition would lead to favorable alteration of CAI pharmacokinetics, and to evaluate the safety, toxicity and tolerability of the proposed combination...
  36. doi Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?
    Minoli A Perera
    Sections of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Pharmacotherapy 28:755-68. 2008
    ..In addition, ethical and logistic implications of pharmacogenetic testing exist...
  37. pmc A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469
    Jacqueline Ramirez
    aDepartment of Medicine, The University of Chicago, Chicago, Illinois bDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, USA
    Pharmacogenet Genomics 24:129-32. 2014
    ..01-0.02) in only one of the two cohorts. Our study provides a starting point for future investigations on the functionality of AOX1 SNPs. However, variability in XK469 clearance cannot be attributed to polymorphisms in AOX1. ..
  38. ncbi UGT pharmacogenomics: implications for cancer risk and cancer therapeutics
    Apurva A Desai
    Department of Medicine, The University of Chicago, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Pharmacogenetics 13:517-23. 2003
    ..This article focuses on the potential impact of various UGTs or their variants on cancer risk and cancer therapeutics...
  39. ncbi "Irinogenetics" and UGT1A: from genotypes to haplotypes
    Federico Innocenti
    Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, Cancer Research Center, University of Chicago, IL 60637, USA
    Clin Pharmacol Ther 75:495-500. 2004
  40. ncbi In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes
    Jacqueline Ramirez
    Department of Medicine, University of Chicago, Illinois 60637, USA
    Pharm Res 19:588-94. 2002
    ....
  41. doi Individualizing dosing of irinotecan
    Mark J Ratain
    Section of Hematology Oncology, Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, and Cancer Research Center, The University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 16:371-2. 2010
    ..Irinotecan is an interesting agent for individualized dosing, given its complex metabolism and increasing knowledge of its pharmacokinetics predictors...
  42. pmc Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)
    Hedy Lee Kindler
    University of Chicago Cancer Research Center, Chicago, IL 60637 1470, USA
    J Clin Oncol 28:3617-22. 2010
    ..These encouraging data led Cancer and Leukemia Group B (CALGB) to conduct a double-blind, placebo-controlled, randomized phase III trial of gemcitabine/bevacizumab versus gemcitabine/placebo in advanced pancreatic cancer patients...
  43. doi Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease
    Peter H O'Donnell
    Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 51:2240-9. 2010
    ..This AUC is now being studied in phase II for patients receiving busulfan/fludarabine/alemtuzumab as alloHCT conditioning...
  44. pmc The use of genomic information to optimize cancer chemotherapy
    Federico Innocenti
    Department of Medicine, Comprehensive Cancer Center, The University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 38:186-95. 2011
    ..We present a perspective and summary of the challenges and opportunities in translating heritable genomic discoveries to patients...
  45. pmc A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303
    Federico Innocenti
    Department of Medicine, Cancer and Leukemia Group B CALGB, University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 18:577-84. 2012
    ..We prospectively collected germline DNA and conducted a genome-wide association study (GWAS) using overall survival (OS) as the endpoint...
  46. doi Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transporters
    Dylan M Glubb
    Department of Medicine, University of Chicago, Chicago, IL, USA
    Wiley Interdiscip Rev Syst Biol Med 3:299-313. 2011
    ..It also still remains to be seen whether these findings have clinical implications for drug therapy but the realization of personalized medicine is a possible consequence of this research...
  47. ncbi Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls
    Federico Innocenti
    Clin Cancer Res 8:1314; author reply 1315-6. 2002
  48. ncbi Insights, challenges, and future directions in irinogenetics
    Tae Won Kim
    Section of Oncology, Department of Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea
    Ther Drug Monit 29:265-70. 2007
    ..The pharmacogenetics of irinotecan (irinogenetics) is one of few promising examples of the application of pharmacogenetics to individualized drug therapy. This review summarizes ongoing studies and unanswered questions on irinogenetics...
  49. ncbi The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity
    Roshni P Ramchandani
    Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, WO21 Rm 3667, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
    J Clin Pharmacol 47:78-86. 2007
    ..The label modifications also included recommendations for lower starting doses of irinotecan in patients homozygous for the UGT1A1*28 (7/7) polymorphism...
  50. ncbi Irinogenetics: what is the right star?
    Federico Innocenti
    J Clin Oncol 24:2221-4. 2006
  51. ncbi Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
    Int J Cancer 103:294-9. 2003
    ..0004). In conclusion, our data suggest that the TT MTHFR 677 genotype is associated with marked MTX-induced hyperhomocysteinemia and could represent a pharmacogenetic marker for toxicity after chronic treatment with low doses of MTX...
  52. ncbi MTHFR and ALL risk: a challenge
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology Unit, CRO National Cancer Institute, Aviano, Italy
    Leuk Lymphoma 47:1203-4. 2006
  53. ncbi Linkage disequilibrium across the UGT1A locus should not be ignored in association studies of cancer susceptibility
    Wanqing Liu
    Clin Cancer Res 11:1348-9; author reply 1349. 2005
  54. ncbi Translation of pharmacogenetic knowledge into cancer therapeutics
    Wei Peng Yong
    Department of Haematology Oncology, National University Hospital, Singapore 119074
    Clin Adv Hematol Oncol 5:698-706. 2007
    ..This review gives an overview of pharmacogenetic methods and focuses on the application of pharmacogenetic knowledge in oncology, using the examples of 6-mercaptopurine, irinotecan, tamoxifen, and gefitinib...